With Johnson & Johnson (JNJ) recently hitting 52-week lows and falling to the 3% yield threshold, there has been a lot of buzz around the stock recently. Last month, Seeking Alpha published an article in response to Mike Nadel’s #1 Stock in the World series update, and commenters had a lot of good things to say about JNJ. It’s not surprising that investors, many of whom are focused on dividend income/growth, would flock to a high quality name like this (JNJ is one of two companies in the world with an AAA rated balance sheet, Microsoft (NASDAQ:MSFT) is the other) when it’s trading at the cheapest valuation investors have seen in years. Dividend Sensei also recently covered the stock, penning a wonderful bullish piece on the name, claiming that JNJ “Could Crush the Market Over the Next Decade.” I’ve owned JNJ for years, though I recently trimmed the position, locking in strong gains at $130.30 due primarily to the Talc litigation headwinds. I maintained exposure to the majority of my shares; however, I was sitting on nice gains on a lot owned in a retirement account and decided to reduce my exposure (and risk) without tax penalties, waiting to see how things shook out. Well, flash forward a couple of months and JNJ shares seem to have found support in the ~$120 area, so I decided to buy those shares back at a ~6.6% discount to my previous sale.
Recent Purchase: Johnson & Johnson
6/14/18
Stories you Need to Know
- David Nevins Interviews Dr. Matthew Frieman, Associate Professor, University of Maryland School of Medicine
- Immunic Reports Year End 2020 Financial Results
- Amneal Reports Fourth Quarter and Full Year 2020 Financial Results
- Relivant to Acquire Silicon Therapeutics for $450 Million
- Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
- Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results
- MTBC Reports Record Full Year 2020 Results
- Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update

